INCY Quote, Financials, Valuation and Earnings

Insmed, Inc. has a net margin of 19.86% compared to Incyte Corp.'s net margin of -124.5%. Incyte Corp.'s return on equity of 30.48% beat Insmed, Inc.'s return on equity of -192.35%.

Incyte Corp. has a consensus price target of $107.09, signalling upside risk potential of 5.75%. On the other hand Insmed, Inc. has an analysts' consensus of $212.53 which suggests that it could grow by 42.32%. Given that Insmed, Inc. has higher upside potential than Incyte Corp., analysts believe Insmed, Inc. is more attractive than Incyte Corp..

Incyte Corp. has a beta of 0.825, which suggesting that the stock is 17.542% less volatile than S&P 500. In comparison Insmed, Inc. has a beta of 1.105, suggesting its more volatile than the S&P 500 by 10.538%.

Incyte Corp. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Insmed, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Incyte Corp. pays -- of its earnings as a dividend. Insmed, Inc. pays out -- of its earnings as a dividend.

Incyte Corp. quarterly revenues are $1.5B, which are larger than Insmed, Inc. quarterly revenues of $263.8M. Incyte Corp.'s net income of $299.3M is higher than Insmed, Inc.'s net income of -$328.5M. Notably, Incyte Corp.'s price-to-earnings ratio is 15.82x while Insmed, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Incyte Corp. is 3.96x versus 48.98x for Insmed, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Eli Lilly & Co. has a net margin of 19.86% compared to Incyte Corp.'s net margin of 34.4%. Incyte Corp.'s return on equity of 30.48% beat Eli Lilly & Co.'s return on equity of 104.39%.

Incyte Corp. has a consensus price target of $107.09, signalling upside risk potential of 5.75%. On the other hand Eli Lilly & Co. has an analysts' consensus of $1,214.34 which suggests that it could grow by 15.43%. Given that Eli Lilly & Co. has higher upside potential than Incyte Corp., analysts believe Eli Lilly & Co. is more attractive than Incyte Corp..

Incyte Corp. has a beta of 0.825, which suggesting that the stock is 17.542% less volatile than S&P 500. In comparison Eli Lilly & Co. has a beta of 0.388, suggesting its less volatile than the S&P 500 by 61.171%.

Incyte Corp. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Eli Lilly & Co. offers a yield of 0.59% to investors and pays a quarterly dividend of $1.73 per share. Incyte Corp. pays -- of its earnings as a dividend. Eli Lilly & Co. pays out 26.14% of its earnings as a dividend. Eli Lilly & Co.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Incyte Corp. quarterly revenues are $1.5B, which are smaller than Eli Lilly & Co. quarterly revenues of $19.3B. Incyte Corp.'s net income of $299.3M is lower than Eli Lilly & Co.'s net income of $6.6B. Notably, Incyte Corp.'s price-to-earnings ratio is 15.82x while Eli Lilly & Co.'s PE ratio is 46.57x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Incyte Corp. is 3.96x versus 14.70x for Eli Lilly & Co.. Usually stocks with elevated PS ratios are considered overvalued.

Madrigal Pharmaceuticals, Inc. has a net margin of 19.86% compared to Incyte Corp.'s net margin of -18.24%. Incyte Corp.'s return on equity of 30.48% beat Madrigal Pharmaceuticals, Inc.'s return on equity of -42.53%.

Incyte Corp. has a consensus price target of $107.09, signalling upside risk potential of 5.75%. On the other hand Madrigal Pharmaceuticals, Inc. has an analysts' consensus of $667.57 which suggests that it could grow by 54.53%. Given that Madrigal Pharmaceuticals, Inc. has higher upside potential than Incyte Corp., analysts believe Madrigal Pharmaceuticals, Inc. is more attractive than Incyte Corp..

Incyte Corp. has a beta of 0.825, which suggesting that the stock is 17.542% less volatile than S&P 500. In comparison Madrigal Pharmaceuticals, Inc. has a beta of -1.010, suggesting its less volatile than the S&P 500 by 201.017%.

Incyte Corp. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Madrigal Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Incyte Corp. pays -- of its earnings as a dividend. Madrigal Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.

Incyte Corp. quarterly revenues are $1.5B, which are larger than Madrigal Pharmaceuticals, Inc. quarterly revenues of $321.1M. Incyte Corp.'s net income of $299.3M is higher than Madrigal Pharmaceuticals, Inc.'s net income of -$58.6M. Notably, Incyte Corp.'s price-to-earnings ratio is 15.82x while Madrigal Pharmaceuticals, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Incyte Corp. is 3.96x versus 10.10x for Madrigal Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Xencor, Inc. has a net margin of 19.86% compared to Incyte Corp.'s net margin of -23.56%. Incyte Corp.'s return on equity of 30.48% beat Xencor, Inc.'s return on equity of -14.42%.

Incyte Corp. has a consensus price target of $107.09, signalling upside risk potential of 5.75%. On the other hand Xencor, Inc. has an analysts' consensus of $28.83 which suggests that it could grow by 125.79%. Given that Xencor, Inc. has higher upside potential than Incyte Corp., analysts believe Xencor, Inc. is more attractive than Incyte Corp..

Incyte Corp. has a beta of 0.825, which suggesting that the stock is 17.542% less volatile than S&P 500. In comparison Xencor, Inc. has a beta of 0.980, suggesting its less volatile than the S&P 500 by 1.968%.

Incyte Corp. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Xencor, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Incyte Corp. pays -- of its earnings as a dividend. Xencor, Inc. pays out -- of its earnings as a dividend.

Incyte Corp. quarterly revenues are $1.5B, which are larger than Xencor, Inc. quarterly revenues of $28.2M. Incyte Corp.'s net income of $299.3M is higher than Xencor, Inc.'s net income of -$6.7M. Notably, Incyte Corp.'s price-to-earnings ratio is 15.82x while Xencor, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Incyte Corp. is 3.96x versus 7.55x for Xencor, Inc.. Usually stocks with elevated PS ratios are considered overvalued.